HUTCHMED (China) Ltd (HCM): Operating Cash Flow
-$64.66M
Year ended 2025-12-31
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$64.66M | n/m | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $497.0K | -99.8% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $219.26M | n/m | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | -$268.60M | n/m | 2025-03-19, From 2022-01-01 |
| 2021-12-31 | -$204.22M | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | -$62.07M | n/m | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | -$80.91M | n/m | 2022-03-03, From 2019-01-01 |
| 2018-12-31 | -$32.85M | n/m | 2021-03-04, From 2018-01-01 |
| 2017-12-31 | -$8.94M | n/m | 2020-03-03, From 2017-01-01 |
| 2016-12-31 | -$9.57M | n/m | 2019-03-11, From 2016-01-01 |
| 2015-12-31 | -$9.38M | n/m | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | $8.36M | n/a | 2017-03-13, From 2014-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | -$64.66M | n/m |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | -$10.31M | n/m |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $55.83M | +440.7% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | -$445.91M | n/m |
| Insmed Inc (INSM) | 2025-12-31 | -$935.01M | n/m |
| Opko Health, Inc. (OPK) | 2025-12-31 | -$178.54M | n/m |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $37.78M | n/m |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | -$24.77M | n/m |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $35.32M | +39.6% |
Compare HCM, ORGO, MIRM, BBIO side by side · Screen every company in Pharmaceutical Preparations ↗